Manufacturers of medicines, including Pfizer and Eli Lilly, have spent a combined $450,000 lobbying against price caps on ...

The FDA has approved two new biosimilars of denosumab-dssb to treat osteoporosis, increase bone mass, prevent ...

Samsung Bioepis’ biosimilars Ospomyv and Xbryk have been approved to be interchangeable with Prolia/Xgeva treat osteoporosis ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Substack by Disruptive analytics. In this article, we will summarize ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Mike Edmondson Mike Edmondson, a U.S. Marine Corps veteran and vice president of performance optimization at Amgen, has joined the advisory council of ...

Amgen Inc. closed 16.06% short of its 52-week high of $346.85, which the company reached on July 25th.

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

Amgen will continue to advance half of the combo, PRMT5 inhibitor AMG 193, for which it is running a mid-stage trial in ...

Combining talazoparib with enzalutamide significantly improves overall survival in patients with metastatic ...

Gladstone Institutional Advisory LLC trimmed its holdings in Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.9% in the fourth ...